申请人:SANKYO COMPANY LIMITED
公开号:EP0745600A1
公开(公告)日:1996-12-04
Compounds of formula (I):
[in which: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.
式(I)化合物:
其中X 代表任选取代的苯并咪唑基团;Y 代表氧原子或硫原子;Z 代表 2,4-二氧代噻唑啉-5-亚基甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代噁二唑啉-2-基甲基或 N-羟基脲基甲基;R 代表氢、烷基、烷氧基、卤素、羟基、硝基、氨基或芳烷基;以及 m 是 1 至 5 的整数];具有治疗和/或预防多种疾病的重要活性,包括以下一种或多种疾病:高血脂症、高胆固醇血症、高血压、高血糖、高胆固醇血症、高胆固醇血症、高胆固醇血症、高胆固醇血症、高胆固醇血症和高胆固醇血症:高血脂、高血糖、肥胖、糖耐量减低(IGT)、胰岛素抵抗和糖尿病并发症中的一种或多种。